HAYA Therapeutics

Name

HAYA Therapeutics

Legal name

HAYA Therapeutics SA

Website

https://hayatx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

RNA-targeted Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) (HLAAADAC)

akta.pro secondary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• RNA-guided therapeutics
• Antisense oligonucleotide therapy
• Non-coding RNA discovery
• Cardiac fibrosis treatment
• Regulatory genome platform

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Biopharma Partnerships & Licensing (Lilly collaboration): Multi-year collaboration with Eli Lilly (announced Sept 2024) for discovery of RNA-based drug targets in obesity and metabolic disorders. HAYA receives an upfront payment (including equity investment) and is eligible for up to an aggregate $1 billion in pre-clinical, clinical and commercial milestone payments, plus royalties on product sales. Revenue is milestone-driven and not recurring.
2. Venture Capital Financing (Pre-Revenue): HAYA is a clinical-stage biotechnology company that is pre-revenue. Capital is raised through equity financing rounds (CHF 18M seed in 2021, US$5M seed extension in 2022 bringing total seed to ~US$25M, US$65M Series A in 2025) led by Sofinnova Partners, Earlybird Venture Capital, Eli Lilly, and other investors. No product sales or commercial revenue yet.
3. Future Product Sales (HTX-001, pipeline): Lead candidate HTX-001 is an antisense oligonucleotide currently in Phase 1 clinical trials (first cohort dosed May 2026) for nonobstructive hypertrophic cardiomyopathy (nHCM); future revenue would come from commercialization of RNA-guided therapeutics in cardiac, pulmonary, and oncology indications, plus future out-licensing deals.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

HAYA Therapeutics develops precision RNA-guided medicines (antisense oligonucleotides) that target long non-coding RNAs in the 'dark genome' to reprogram disease-driving cell states. Its lead candidate HTX-001 is an anti-WISPER ASO in Phase 1 clinical trials for nonobstructive hypertrophic cardiomyopathy (nHCM), with additional pipeline programs in pulmonary fibrosis, oncology, and metabolic diseases. The company operates a partnership-driven business model, exemplified by its multi-year Eli Lilly collaboration for obesity and metabolic disease drug targets.

Product overview

HAYA Therapeutics offers a platform-plus-programs architecture centered on its proprietary HAYAtlas (Regulatory Genome Engine) — a causally-informative atlas combining multimodal functional genomics with computational and machine learning methodologies to decode the 98% of the genome that does not code for proteins. Built on this core platform, HAYA develops a portfolio of first-in-class RNA-guided antisense oligonucleotide (ASO) therapeutics, with its lead candidate HTX-001 (Wisper) in Phase 1 clinical development for nonobstructive hypertrophic cardiomyopathy (nHCM). The same platform powers additional pipeline programs spanning pulmonary (idiopathic pulmonary fibrosis & rejuvenation), oncology (solid tumors), and new discovery programs in other common and chronic diseases, all accelerated through strategic collaborations.

Differentiator

Problem solved

Functional benefit

Brands

• HAYAtlas: Proprietary unified, scalable engine (HAYAtlas™) that links non-coding RNAs to complex disease causality and predicts their potential to reprogram cell fate, powering HAYA's target nomination.
• DiscoverHAYA

Products and services

• HTX-001 (anti-WISPER ASO) HAYA's lead investigational candidate — a first-in-class antisense oligonucleotide designed to downregulate WISPER lncRNA, a heart stress-specific long non-coding RNA overexpressed in patients with hypertrophic cardiomyopathy. The therapeutic targets WISPER in cardiac myofibroblast cells to promote cell-state reprogramming of the fibrotic/pathological cell population back to a healthy state. Currently in Phase 1a/b clinical trial for nonobstructive hypertrophic cardiomyopathy (nHCM).
• Pulmonary Program (Idiopathic Pulmonary Fibrosis & Rejuvenation) HAYA's pulmonary pipeline program targeting idiopathic pulmonary fibrosis (IPF) and lung rejuvenation. Developed using the HAYAtlas platform to identify lncRNA targets in pulmonary fibrosis and lung cell states. Target identity currently undisclosed.
• Oncology Program (Solid Tumors) HAYA's oncology pipeline program targeting solid tumors using lncRNA-targeting precision RNA therapies. Modality is currently agnostic. Leverages the HAYAtlas platform for target identification in tumor-related cell states.
• New Discovery Programs HAYA's broader new discovery programs targeting other common and chronic diseases, accelerated through strategic collaborations. Builds on the versatility of the HAYAtlas platform to address additional fibrotic, metabolic, and age-related disease indications.
• RNA-Guided Discovery Collaboration (Eli Lilly multi-year program for obesity and metabolic disease) A co-development and out-licensing offering in which HAYA applies its proprietary RNA-guided regulatory genome platform to identify and validate multiple RNA-based drug targets in obesity and metabolic disease for Eli Lilly. HAYA receives upfront and equity, plus up to $1 billion in potential milestones and royalties — one of the largest collaborations to date in the regulatory genome space.

Quantifiable outcome

• 30–80% new lncRNAs identified per cell-state vs GENCODE
• +5 more outcomes

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core, flagship and minor.

• Lilly Gateway Labs (Lilly Catalyze360 / Alexandria Real Estate Equities)coreStrategic or Co-development Partner · 3 June 2025HAYA relocated its US site to Lilly Gateway Labs in San Diego (operated in partnership with Alexandria Real Estate Equities) on June 3, 2025. The site provides cutting-edge laboratory space, operational support, and access to an evolving ecosystem of biotech innovators, supporting HAYA's multi-modal functional genomics work and clinical development of HTX-001. HAYA remains fully independent and retains all assets and intellectual property.
• Eli Lilly and CompanyflagshipStrategic or Co-development Partner · 4 September 2024Multi-year collaboration (announced Sept 4, 2024) for HAYA to apply its proprietary RNA-guided regulatory genome platform to support preclinical drug discovery in obesity and related metabolic conditions. Partners will identify multiple regulatory-genome-derived RNA-based drug targets. HAYA receives an upfront payment (including equity investment) and is eligible for up to an aggregate $1 billion in pre-clinical, clinical and commercial milestone payments, plus royalties on product sales. Described as one of the largest collaborations to date in the regulatory genome space. Eli Lilly also participated in HAYA's $65M Series A (May 2025) and hosts HAYA's San Diego operations at Lilly Gateway Labs.
• JLABS @ San Diego (Johnson & Johnson Innovation)minorStrategic or Co-development Partner · 9 February 2022HAYA established a new laboratory space at JLABS @ San Diego (part of Johnson & Johnson Innovation's global network of life science incubators) in February 2022, enabling expansion of its US operations alongside the CHF 18M seed round and $5M seed extension. HAYA later relocated to Lilly Gateway Labs in June 2025.
• CHUV (Lausanne University Hospital)coreOEM/ Whitelabel/ Licensing Partner · 21 May 2021HAYA secured an exclusive license from CHUV (Centre Hospitalier Universitaire Vaudois / Lausanne University Hospital) for the Wisper asset, the cardiac-tissue-enriched lncRNA discovered by co-founder Samir Ounzain during his academic research at CHUV. This license is the foundational IP enabling HAYA's lead program HTX-001 (anti-WISPER antisense oligonucleotide) for cardiac fibrosis.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• BridgeBio Pharma: Clinical-stage biotech developing genetic and cardiovascular medicines, including programs targeting hypertrophic cardiomyopathy (e.g., acoramidis for ATTR-CM). Comparable as a cardiovascular-focused biotech with multiple programs and a pipeline model analogous to HAYA's.
• Alnylam Pharmaceuticals: The leading RNA-targeted therapeutics company, using RNAi rather than ASOs but operating in the same broad RNA-medicine category with a platform-pipeline model and major pharma partnerships analogous to HAYA's Lilly deal.
• Ionis Pharmaceuticals: The foundational antisense oligonucleotide (ASO) company and pioneer of the modality HAYA uses. HAYA's VP Translation (James Karras) previously worked at Ionis, and Ionis serves as the benchmark for ASO-based therapeutic platforms across multiple disease areas.

Direct peers

• Verve Therapeutics: Cardiovascular genetic medicine company developing in vivo gene editing therapies for heart disease. Barry Ticho (HAYA independent director) co-founded Verve, and both companies pursue disease-modifying approaches to cardiac conditions using nucleic-acid-based modalities.
• Stoke Therapeutics: RNA-targeted antisense oligonucleotide company developing precision medicines for genetic diseases, with similar platform-plus-pipeline architecture to HAYA. Notably, Barry Ticho (HAYA independent director) is CMO at Stoke, indicating direct personnel overlap in the ASO/RNA therapeutic space.
• Tenaya Therapeutics: Clinical-stage genetic medicines company focused on heart disease, including hypertrophic cardiomyopathy. Directly comparable to HAYA's cardiac fibrosis/nHCM focus, with competing modalities (gene therapy, small molecules) targeting similar patient populations.
• LEXEO Therapeutics: Cardiology-focused genetic medicine company developing RNA- and gene-therapy-based treatments for cardiovascular diseases. HAYA's CMO Jordan Shin was previously SVP at LEXEO, and both companies target overlapping cardiac indications including cardiomyopathies.
• Dyne Therapeutics: Clinical-stage RNA-targeted therapeutics company developing antisense oligonucleotides for serious muscle diseases. Directly comparable modality (ASOs) and platform architecture to HAYA, though focused on muscle rather than cardiac/fibrotic indications.

Emerging players

• Skyhawk Therapeutics: RNA-targeting small molecule developer with a platform-plus-pipeline model focused on splicing and RNA biology. Comparable to HAYA as a platform company leveraging proprietary RNA-biology science to generate a portfolio of therapeutics across multiple indications.

Others

• Recursion Pharmaceuticals: AI-driven drug discovery platform using computational biology and high-throughput experimentation. HAYA's CBO Richard Law helped lead the Recursion/Exscientia merger, and Recursion's platform-plus-pharma-partnership model parallels HAYA's strategy of leveraging proprietary biology/AI tools to secure large-pharma collaborations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/HaYaTherapx
• LinkedInlinkedin.com/company/haya-therapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds12 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HAYA Therapeutics